Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase 1 Clinical Trials.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2929
Abstract: Rozibafusp alfa (AMG 570) is a first-in-class bispecific IgG2-peptide fusion designed to inhibit inducible T-cell costimulator ligand (ICOSL) and B-cell activating factor (BAFF). The pharmacokinetics (PK) and pharmacodynamics (PD) of rozibafusp alfa were investigated in… read more here.
Keywords: baff; rozibafusp alfa; bispecific; icosl ... See more keywords
Attenuate ICOSL and IL-27 in Aire-overexpressing DC2.4 cells suppress TFH cell differentiation.
Sign Up to like & getrecommendations! Published in 2021 at "Immunobiology"
DOI: 10.1016/j.imbio.2021.152147
Abstract: Autoimmune regulator (Aire) is a transcription factor that plays a pivotal role in the maintenance of immune tolerance. However, little is known about its roles in peripheral immune tolerance. Aire is predominantly expressed in dendritic… read more here.
Keywords: dc2 cells; cell differentiation; aire; tfh cell ... See more keywords
Increased B-cell ICOSL Expression Improves Chemotherapy Response.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-039
Abstract: A chemotherapy-induced shift to ICOSL+ B cells in breast tumors correlated with better survival. read more here.
Keywords: icosl expression; icosl; increased cell; cell icosl ... See more keywords